Transcranial Direct Current Stimulation to Enhance Training Effectiveness in Chronic Post-Stroke Aphasia

June 5, 2023 updated by: University Medicine Greifswald
The aim of the study is to investigate whether intensive speech-language therapy (SLT) combined with anodal transcranial direct current stimulation (tDCS) leads to better communication performance than SLT combined with placebo stimulation (using sham-tDCS).

Study Overview

Detailed Description

Intensive speech-language therapy (SLT) can promote recovery from chronic post-stroke aphasia, but effect sizes are moderate. This highlights the pressing need to explore adjunct strategies, such as transcranial direct current stimulation (tDCS), to enhance training effectiveness. Recently, the investigators provided evidence from a single-center randomized controlled trial (RCT) suggesting that anodal-tDCS of the left primary motor cortex (M1) improves naming and communication ability in chronic post-stroke aphasia, with medium-to-large effect sizes. However, prior to integration into clinical routine, a multi-center RCT with adequate power, duration, and outcomes relevant to everyday life is required, which is the goal of the present study. After trial completion, a workshop with relevant stakeholders will ensure transfer into best-practice guidelines.

Study Type

Interventional

Enrollment (Estimated)

130

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Aachen, Germany, 52074
        • Recruiting
        • Aphasiestation RWTH Aachen
        • Contact:
      • Allensbach, Germany, 78476
      • Bad Aibling, Germany, 83209
        • Recruiting
        • Schön Klinik Bad Aibling Harthausen
        • Contact:
      • Bad Homburg, Germany, 61348
        • Recruiting
        • Wicker Klinik Bad Homburg
        • Contact:
      • Bad Klosterlausnitz, Germany, 07639
      • Bad Sülze, Germany, 18334
      • Berlin, Germany, 10115
      • Gailingen, Germany, 78262
      • Greifswald, Germany, 17475
      • Greifswald, Germany, 17491
      • Göppingen, Germany, 73035
      • Heidelberg, Germany, 69117
      • Kempen, Germany, 47906
        • Recruiting
        • Hospital zum Heiligen Geist Kempen
        • Contact:
      • Leipzig, Germany, 04103
      • Lindlar, Germany, 51789
      • Marbach, Germany, 71672
      • Meerbusch, Germany, 40670
        • Recruiting
        • St. Mauritius Therapieklinik
        • Contact:
      • Vechta, Germany, 49377
        • Recruiting
        • Aphasie-Zentrum Vechta gGmbH
        • Contact:
          • Stephan Benhamza
          • Phone Number: 04447/970134
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • left-hemisphere cortical or subcortical stroke with first-ever aphasic symptoms
  • at least 6 months post-onset of stroke;
  • aphasia, as determined by the Aachen Aphasia Test (AAT);
  • 13 moderate-to-severe word finding difficulties (maximum of 75% correct items on a computerized naming task at baseline);
  • at least 1 correct reaction on the first part of the AAT subscale Token Test (ensuring basic comprehension skills);
  • at least 1 point on the communicative task of the AAT subscale Spontaneous Speech (ensuring basic communication abilities);
  • German as first language;
  • intact left-hemisphere "hand knob" without right prefrontal lesions for placement of tDCS electrodes, as confirmed by magnetic resonance imaging or computer tomography scans.

Exclusion Criteria:

  • contraindications for tDCS (e.g., cardiac pacemaker, history of seizures, implanted metal inside the head);
  • more than one clinically apparent stroke with aphasic symptoms;
  • other severe neurological diseases (e.g., brain tumor, and subdural hematoma);
  • epilepsy with seizures during the last 12 months prior to study start and/or intake of sedating antiepileptic drugs (barbiturates and benzodiazepines),
  • history of severe alcohol or drug abuse;
  • current severe depression;
  • current psychosis or other relevant psychiatric condition;
  • very severe apraxia of speech, as revealed by Hierarchical Word Lists;
  • severe non-verbal cognitive deficits, as indicated by the Corsi Block-Tapping Task;
  • severe uncontrolled medical problems;
  • severely impaired vision or hearing that prevents patients from engaging in intensive SLT;
  • changes in centrally active drugs within 2 weeks prior to study inclusion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental group
Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
Sham Comparator: Control group
Placebo stimulation (using sham-tDCS) combined with SLT
Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in communication ability, as assessed by the Amsterdam Nijmegen Everyday Language Test
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Amsterdam Nijmegen Everyday Language Test (A-scale; parallel versions used in counterbalanced order across participants); cf. Blomert L, Kean ML, Koster C, et al. Amsterdam-Nijmegen Everyday Language Test-Construction, Reliability and Validity. Aphasiology 1994; 8: 381-407.
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in naming ability, as assessed based on personally relevant trained and untrained items, consistent with previous work (see description)
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Personally relevant trained and untrained items, consistent with previous work; cf. Meinzer M, Darkow R, Lindenberg R, et al. Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. Brain 2016; 139: 1152-1163.
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Change in (non-)verbal communication, as assessed by the Scenario Test
Time Frame: Before the 3-week treatment period; 6-month follow-up
Scenario Test; cf. Nobis-Bosch R, Abel S, Krzok F, et al. Szenario Test-Testung verbaler und nonverbaler Aspekte aphasischer Kommunikation. ProLog, in preparation.
Before the 3-week treatment period; 6-month follow-up
Change in (non-)verbal communication, as assessed by the Communicative Effectiveness Index
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Communicative Effectiveness Index; cf. Lomas J, Pickard L, Bester S, et al. The Communicative Effectiveness Index: development and psychometric evaluation of a functional communication measure for adult aphasia. J Speech Hear Disord 1989; 54: 113-124.
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Change in attention and executive function, as assessed by the subscales Go/NoGo and Alertness from Test of Attentional Performance
Time Frame: Before the 3-week treatment period; 6-month follow up
Subscales Go/NoGo and Alertness from Test of Attentional Performance; cf. Zimmermann P and Fimm B. Testbatterie zur Aufmerksamkeitsprüfung (TAP). Herzogenrath: PSYTEST Verlag, 2002.
Before the 3-week treatment period; 6-month follow up
Change in non-verbal episodic memory, as assessed by the Figure Recognition Task from Benton Visual Retention Test
Time Frame: Before the 3-week treatment period; 6-month follow up
Figure Recognition Task from Benton Visual Retention Test; cf. Benton Sivan A and Spreen O. Benton Test. Bern: Huber, 2009.
Before the 3-week treatment period; 6-month follow up
Change in mood, as assessed by the German version of the 10-item Stroke Aphasic Depression Questionnaire
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
German version of the 10-item Stroke Aphasic Depression Questionnaire (SADQH-10); cf. Cobley CS, Thomas SA, Lincoln NB, et al. The assessment of low mood in stroke patients with aphasia: reliability and validity of the 10-item Hospital version of the Stroke Aphasic Depression Questionnaire (SADQH-10). Clin Rehabil 2012; 26: 372-381.
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Change in health-related quality of life, as assessed by the Stroke and Aphasia Quality of Life Scale
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Stroke and Aphasia Quality of Life Scale (SAQOL-39g); cf. Hilari K, Lamping DL, Smith SC, et al. Psychometric properties of the Stroke and Aphasia Quality of Life Scale (SAQOL-39) in a generic stroke population. Clin Rehabil 2009; 23: 544-557.
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Change in health-related quality of life, as assessed by the EuroQol Health-Related Quality of Life Questionnaire
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
EuroQol Health-Related Quality of Life Questionnaire (EQ-5D-5L); cf. EuroQol G. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Change in direct and indirect costs during the 12-month study period, as assessed by the self-developed Patient Resource Consumption Questionnaire
Time Frame: Before the 3-week treatment period; 6- and 12-month follow ups
Direct and indirect costs during the 12-month study period, as determined by the self-developed Patient Resource Consumption Questionnaire considering common standardized unit cost assumptions.
Before the 3-week treatment period; 6- and 12-month follow ups
Change in direct and indirect costs during the 12-month study period, as assessed by the Quality-Adjusted Life Years
Time Frame: Before the 3-week treatment period; 6- and 12-month follow ups
Quality-Adjusted Life Years; cf. Whitehead SJ and Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010; 96: 5-21.
Before the 3-week treatment period; 6- and 12-month follow ups
Change in unpaid support provided by family members or friends, as assessed by the Burden of informal caregivers
Time Frame: Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups
Burden of informal caregivers; cf. van Exel NJ, Koopmanschap MA, van den Berg B, et al. Burden of informal caregiving for stroke patients. Identification of caregivers at risk of adverse health effects. Cerebrovasc Dis 2005; 19: 11-17.
Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Agnes Floeel, Prof., University Medicine Greifswald

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 6, 2019

Primary Completion (Estimated)

February 4, 2024

Study Completion (Estimated)

August 4, 2024

Study Registration Dates

First Submitted

April 16, 2019

First Submitted That Met QC Criteria

April 25, 2019

First Posted (Actual)

April 29, 2019

Study Record Updates

Last Update Posted (Actual)

June 6, 2023

Last Update Submitted That Met QC Criteria

June 5, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aphasia

Clinical Trials on Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)

3
Subscribe